GlassScriptPhysician profile
Kelli H Dyer
NPI 1235385766
$6,341.98
in general payments reported to CMS, 2019-2025
26 companies · $835 in 2025
The $835 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $967 · 2020: $803 · 2021: $565 · 2022: $300 · 2023: $1,811 · 2024: $1,061 · 2025: $835.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,838 · Travel and Lodging: $869.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,838.34 |
| Travel and Lodging | $868.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,456.22 | 2021-2025 | Lensx, Clareon, Tryptyr |
| Abbvie INC. | $983.79 | 2022-2025 | Lumigan, Alphagan P, Vuity |
| Allergan, INC. | $957.89 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $519.92 | 2020-2025 | Cequa |
| Amgen INC. | $403.68 | 2024-2025 | Tepezza |
| Novartis Pharmaceuticals Corporation | $253.58 | 2019-2022 | |
| Horizon Therapeutics Plc | $211.28 | 2023 | Tepezza |
| Bausch & Lomb Americas INC. | $200.65 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Shire North American Group INC | $179.21 | 2019 | |
| Oyster Point Pharma, INC. | $169.27 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Tarsus Pharmaceuticals, INC. | $152.67 | 2024-2025 | Xdemvy |
| Kala Pharmaceuticals, INC. | $147.23 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $131.66 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $125.00 | 2019 | |
| Mallinckrodt Hospital Products INC. | $92.99 | 2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $64.88 | 2019 | |
| Rxsight INC | $60.88 | 2024-2025 | Light Adjustable Lens (Lal), Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Astellas Pharma US INC | $43.04 | 2025 | Izervay |
| Ani Pharmaceuticals, INC. | $32.69 | 2024 | Purified Cortrophin Gel |
| Harrow Eye, LLC | $29.67 | 2025 | |
| Alimera Sciences, INC. | $26.02 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $23.50 | 2019 | |
| Dompe US, INC. | $23.41 | 2021 | |
| Thea Pharma INC. | $20.62 | 2024 | Iyuzeh |
| Aerie Pharmaceuticals, INC. | $18.39 | 2019 | |
| Eyevance Pharmaceuticals LLC | $13.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelli Dyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.